

May 26, 2026

To, BSE Limited , 25, P. J. Towers, Dalal Street, Mumbai – 400 001 Ref: Company Scrip Code: 532834	To, Listing Department, National Stock Exchange of India Ltd. , Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai- 400051 Ref: Symbol: CAMLINFINE Series: EQ
---	--

Sub: Outcome of the Board Meeting: Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time (“Listing Regulations”) (read with Schedule III).

Dear Sir/Madam,

This is to inform you that the Board of Directors, at its meeting held today i.e. on Tuesday, May 26, 2026, inter alia, approved the following:

A. Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time (“Listing Regulations”)

1. Financial Statements / Results:

This has reference to our intimation dated May 20, 2026.

The Audited Financial Statements (Consolidated and Standalone) for the year ended March 31, 2026 and the Audited Financial Results (Consolidated and Standalone) for the quarter / year ended March 31, 2026, as recommended by the Audit Committee.

Pursuant to Regulation 33 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following as Annexure 1:

- i. Audited Financial Results (Consolidated and Standalone) for the quarter / year ended March 31, 2026; and
- ii. Auditor’s Reports with unmodified opinions on the aforesaid Audited Financial Results (Consolidated and Standalone).

The same are also being uploaded on the Company’s Website (<https://www.camlinfs.com/>). The said Results shall be published in newspapers as per the Listing Regulations.

2. Unmodified Opinion:

We do hereby declare that the statutory auditor of the Company M/s. Kalyaniwalla & Mistry LLP, Chartered Accountants (Firm Registration No.: 104607W/W100166) have issued auditor’s reports with an unmodified opinion on the Audited Standalone and Audited Consolidated Financial Statements for the financial year ended March 31, 2026. This declaration is made pursuant to Regulation 33(3)(d) of the Listing Regulations.



Registered Office:

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
CIN: L74100MH1993PLCO75361



+91 22 6700 1000



+91 22 2832 4404



corporate@camlinfs.com



www.camlinfs.com

3. Annual General Meeting:

The 33rd Annual General Meeting ('AGM') of the Company will be held on Tuesday, August 11, 2026 at 10.00 a.m. through the permissible mode.

B. Disclosure under Regulation 30 of the Listing Regulations (read with Schedule III)

- 4a. Based on the recommendation of the Audit Committee, the Board has approved the appointment of M/s. ABK & Associates, Cost Accountants as the Cost Auditors of the Company for the financial year ending March 31, 2027.
- 4b. Based on the recommendation of the Audit Committee, the Board has approved the appointment of M/s. Mahajan & Aibara, Chartered Accountants as the Internal Auditor of the Company for the financial year ending March 31, 2027.
- 4c. Based on the recommendations of the Audit Committee and the Nomination and Remuneration Committee, the Board has approved the appointment of Mr. Pankaj Pandey as Chief Financial Officer (CFO) and Key Managerial Personnel of the Company, effective August 18, 2026, on such remuneration and terms and conditions as approved by the Nomination and Remuneration Committee. Upon Mr. Pandey's joining as CFO, Mr. Santosh Parab will cease to hold the office of CFO and will be re-designated as President – Strategy and Global CFO, of the Company.
- 4d. Based on the recommendations of the Audit Committee and the Nomination and Remuneration Committee, the Board has approved the re-designation of Mr. Santosh Parab, currently Chief Financial Officer, as President – Strategy and Global CFO, effective August 18, 2026, upon the joining of Mr. Pankaj Pandey as CFO, on such remuneration and terms and conditions as may be approved by the Nomination and Remuneration Committee.

Disclosures under Regulation 30 of read with Schedule III of the SEBI Listing Regulations and SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026 are enclosed as Annexure 2.

The above information is also available on the Company's Website (<https://www.camlinfs.com/>).

The Board meeting commenced at 01:30 p.m. (IST) and concluded at 03:40 p.m. (IST).

This is for your information and record please.

Encl.: a/a.

Thanking You,

For Camlin Fine Sciences Limited

Rahul Sawale
Company Secretary
& VP - Legal



Registered Office:

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
CIN: L74100MH1993PLCO75361



+91 22 6700 1000



+91 22 2832 4404



corporate@camlinfs.com



www.camlinfs.com

CAMLIN FINE SCIENCES LIMITED
STATEMENT OF AUDITED FINANCIAL RESULTS FOR QUARTER AND YEAR ENDED MARCH 31, 2026

(Rs.in Lakh, except per share data)

	PARTICULARS	STANDALONE					CONSOLIDATED				
		QUARTER ENDED			YEAR ENDED		QUARTER ENDED			YEAR ENDED	
		31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025	31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025
		(Audited) (Refer Note 2)	(Unaudited)	(Audited) (Refer Note 2)	(Audited)	(Audited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited) (Refer Note 2)	(Audited)	(Audited)
1	Revenue from operations	18,351.65	21,892.16	27,259.63	83,791.82	88,649.13	42,481.12	44,051.07	43,158.42	172,330.81	162,868.75
2	Other income	1,530.19	576.69	893.66	3,495.11	2,061.53	2,391.22	268.02	1,118.83	2,879.23	1,516.19
3	Total income	19,881.84	22,468.85	28,153.29	87,286.93	90,710.66	44,872.34	44,319.09	44,277.25	175,210.04	164,384.94
4	Expenses										
	Cost of materials consumed	7,767.91	11,068.08	15,002.87	40,182.17	53,922.47	12,072.85	26,766.44	19,486.59	82,327.03	81,406.51
	Purchase of stock in trade	204.35	80.58	58.24	369.14	1,695.32	1,816.09	1,528.24	236.13	8,860.11	10,492.78
	Changes in inventories of finished goods/WIP/stock in trade	1,680.13	128.83	(326.07)	4,040.47	(7,491.39)	7,989.83	(4,607.97)	1,357.08	1,057.49	(9,547.05)
	Employee benefits expense	1,807.46	1,992.86	1,889.00	7,597.96	7,248.10	6,593.10	6,175.88	4,853.49	24,390.08	18,545.11
	Finance costs	2,205.06	1,486.33	1,743.93	6,698.69	6,611.93	2,298.02	1,725.56	1,493.08	7,293.98	9,629.80
	Depreciation and amortisation expense	1,328.49	1,351.49	1,313.48	5,367.71	5,252.66	2,081.46	1,631.66	1,714.36	7,091.94	6,095.84
	Other expenses	6,290.92	6,721.80	7,308.61	26,813.06	26,214.41	11,890.67	12,080.23	11,019.65	45,008.22	40,366.98
	Total Expenses	21,284.32	22,829.97	26,990.06	91,069.20	93,453.50	44,742.02	45,300.04	40,160.38	176,028.85	156,989.97
5	Profit / (Loss) before exceptional items and share of profit / (loss) of associate (3-4)	(1,402.48)	(361.12)	1,163.23	(3,782.27)	(2,742.84)	130.32	(980.95)	4,116.87	(818.81)	7,394.97
6	Exceptional items (Refer Note 7)	261.14	1,365.81	(26.45)	1,626.95	9,600.21	794.88	1,751.13	559.40	2,546.01	981.52
7	Profit / (Loss) before share of profit / (loss) of associate (5-6)	(1,663.62)	(1,726.93)	1,189.68	(5,409.22)	(12,343.05)	(664.56)	(2,732.08)	3,557.47	(3,364.82)	6,413.45
8	Share of profit / (loss) of associate	-	-	-	-	-	138.29	(25.39)	178.61	166.21	44.22
9	Profit / (Loss) before tax from continuing operations (7-8)	(1,663.62)	(1,726.93)	1,189.68	(5,409.22)	(12,343.05)	(526.27)	(2,757.47)	3,736.08	(3,198.61)	6,457.67
10	Tax Expenses										
	- Current tax	-	-	-	-	165.97	192.09	441.24	1,399.17	1,792.06	4,212.81
	- Deferred tax	(1,098.67)	(427.27)	(372.16)	(2,112.60)	(4,877.97)	(815.75)	(450.11)	(629.68)	(1,837.57)	(4,264.04)
	Total Tax Expenses	(1,098.67)	(427.27)	(372.16)	(2,112.60)	(4,712.00)	(623.66)	(8.87)	769.49	(45.51)	(51.23)
11	Profit / (Loss) from continuing operations for the period (9-10)	(564.95)	(1,299.66)	1,561.84	(3,296.62)	(7,631.05)	97.39	(2,748.60)	2,966.59	(3,153.10)	6,508.90
12	Discontinued operations										
	Profit / (Loss) from discontinued operation before tax	-	-	-	-	-	8,547.12	(961.69)	(2,929.88)	5,524.20	(22,262.96)
	Tax expense of discontinued operations	-	-	-	-	-	16.78	-	25.71	16.78	57.88
	Profit / (Loss) from discontinued operations	-	-	-	-	-	8,530.34	(961.69)	(2,955.59)	5,507.42	(22,320.84)
13	Profit / (Loss) for the period (11+12)	(564.95)	(1,299.66)	1,561.84	(3,296.62)	(7,631.05)	8,627.73	(3,710.29)	11.00	2,354.32	(15,811.94)
14	Other comprehensive income										
A	Items that will not be reclassified to profit or loss										
(i)	Remeasurements of defined benefit plans	65.34	19.67	18.50	(16.10)	(12.26)	69.05	19.67	18.96	(12.39)	(11.80)
(ii)	Income tax relating to Items that will not be reclassified to profit or loss	(22.83)	(6.87)	(6.47)	5.63	4.28	(22.83)	(6.87)	(6.47)	5.63	4.28
B	Items that will be reclassified to profit or loss										
(i)	Exchange differences on translating the financial statements of foreign operations	-	-	-	-	-	(1,093.69)	405.41	384.70	809.59	(1,169.91)
(ii)	The effective portion of gain or loss on hedging instruments in a cash flow hedge	(217.86)	30.24	280.18	(705.71)	(70.81)	(217.86)	30.24	280.18	(705.71)	(70.81)
(iii)	Income tax relating to Items that will be reclassified to profit or loss	76.13	(10.57)	(97.90)	246.60	24.75	76.13	(10.57)	(97.90)	246.60	24.75
	Other comprehensive income	(99.22)	32.47	194.31	(469.58)	(54.04)	(1,189.20)	437.88	579.47	343.72	(1,223.49)
15	Total comprehensive income for the period (13+14)	(664.17)	(1,267.19)	1,756.15	(3,766.20)	(7,685.08)	7,438.53	(3,272.41)	590.47	2,698.04	(17,035.43)



Registered Office:

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
CIN: L74100MH1993PLC075361

+91 22 6700 1000

+91 22 2832 4404

corporate@camlinfs.com

www.camlinfs.com

CAMLIN FINE SCIENCES LIMITED
STATEMENT OF AUDITED FINANCIAL RESULTS FOR QUARTER AND YEAR ENDED MARCH 31, 2026

(Rs.in Lakh, except per share data)

PARTICULARS	STANDALONE					CONSOLIDATED				
	QUARTER ENDED			YEAR ENDED		QUARTER ENDED			YEAR ENDED	
	31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025	31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025
	(Audited) (Refer Note 2)	(Unaudited)	(Audited) (Refer Note 2)	(Audited)	(Audited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited) (Refer Note 2)	(Audited)	(Audited)
16	Profit / (Loss) attributable to:									
(i)	Owners of the Company									
(ii)	Non-controlling interests									
	Profit attributable to owners arises from:									
	Continuing operations									
	Discontinued operations									
17	Other comprehensive income attributable to:									
(i)	Owners of the Company									
(ii)	Non-controlling interests									
18	Total comprehensive income attributable to:									
(i)	Owners of the Company									
(ii)	Non-controlling interests									
	Total comprehensive income attributable to owners arises from:									
	Continuing operations									
	Discontinued operations									
19	Paid-up Equity Share Capital (Face Value Rs.1/- per share)									
20	Other Equity									
	Earnings per Share (EPS) for profit from continuing operation (of Re 1/-each) (not annualised)									
	Basic (Rs.)									
	Diluted (Rs.)									
	Earnings per Share (EPS) for profit from discontinued operation (of Re 1/-each) (not annualised)									
	Basic (Rs.)									
	Diluted (Rs.)									
21	Earnings per Share (EPS) for profit from continuing and discontinued operation (of Re 1/-each) (not annualised)									
	Basic (Rs.)									
	Diluted (Rs.)									



Registered Office:

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
CIN: L74100MH1993PLC075361

+91 22 6700 1000



+91 22 2832 4404



corporate@camlinfs.com



www.camlinfs.com

CAMLIN FINE SCIENCES LIMITED
BALANCE SHEET AS AT March 31, 2026

(Rs.in Lakh)

	PARTICULARS	STANDALONE		CONSOLIDATED	
		31.03.2026 (Audited)	31.03.2025 (Audited)	31.03.2026 (Audited)	31.03.2025 (Audited)
	ASSETS				
(1)	Non-Current Assets				
(a)	Property, Plant and Equipment	48,761.54	52,030.92	56,921.10	59,255.82
(b)	Capital work-in-progress	2,269.68	909.95	3,285.21	972.67
(c)	Right-Of-Use Assets	2,636.35	3,220.32	5,587.83	5,134.59
(d)	Investment Property	-	216.13	-	216.13
(e)	Goodwill	-	-	23,341.05	4,746.71
(f)	Intangible Assets	1,159.67	1,420.09	2,887.37	1,022.64
(g)	Financial Assets				
(i)	Investments	21,708.99	6,353.41	3,026.22	2,296.87
(ii)	Other financial assets	591.39	369.42	1,835.40	1,439.97
(h)	Deferred tax assets (net)	6,588.13	4,223.28	8,738.37	6,503.19
(i)	Income tax assets	739.82	701.31	2,516.23	1,873.31
(j)	Other non-current assets	589.45	484.95	602.37	577.41
	Total Non-current Assets	85,045.02	69,929.78	108,741.15	84,039.31
(2)	Current Assets				
(a)	Inventories	24,350.75	26,315.93	50,374.19	52,685.97
(b)	Financial assets				
(i)	Investments	-	3,801.28	-	3,801.28
(ii)	Trade receivables	47,409.63	41,447.74	37,301.57	32,822.00
(iii)	Cash and cash equivalents	3,621.85	3,606.55	10,855.51	10,407.06
(iv)	Other bank balances	4,466.88	4,858.00	4,466.88	4,973.40
(v)	Loans	5,517.19	5,925.43	-	1,000.00
(vi)	Other financial assets	3,630.02	3,272.61	5,782.92	237.66
(c)	Other current assets	2,930.93	3,710.92	14,651.93	12,412.00
	Total Current Assets	91,927.25	92,938.46	123,433.00	118,339.37
(d)	Asset held for sale	216.13	-	216.13	-
	TOTAL ASSETS	177,188.40	162,868.24	232,390.28	202,378.68
	EQUITY AND LIABILITIES				
(1)	EQUITY				
(a)	Equity Share Capital	1,920.92	1,879.21	1,920.92	1,879.21
(b)	Other Equity	90,961.62	84,347.71	102,167.09	88,288.09
(c)	Non-Controlling Interest	-	-	(4,007.35)	(2,689.37)
	Total Equity	92,882.54	86,226.92	100,080.66	87,477.93
(2)	LIABILITIES				
	Non-current Liabilities				
(a)	Financial Liabilities				
(i)	Borrowings	21,038.50	17,185.96	30,260.59	26,830.33
(ii)	Lease liabilities	403.94	970.91	3,440.22	2,513.60
(iii)	Other financial liabilities	-	-	32.15	38.10
(b)	Provisions	727.54	532.20	727.54	548.43
(c)	Deferred tax liabilities (net)	-	-	390.77	330.97
(d)	Other non-current liabilities	-	-	16.17	18.17
	Total Non-Current Liabilities	22,169.98	18,689.07	34,867.44	30,279.60
(3)	Current Liabilities				
(a)	Financial Liabilities				
(i)	Borrowings	26,139.57	24,045.73	36,547.50	34,784.25
(ia)	Lease liabilities	607.85	615.01	1,760.95	1,051.97
(ii)	Trade Payables				
	(A) Total outstanding dues of micro enterprises and small enterprises; and	8,341.70	5,853.59	8,360.83	5,858.12
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	23,223.32	23,882.70	42,158.47	34,813.65
(iii)	Other financial liabilities	2,531.72	2,327.33	6,177.65	5,189.45
(b)	Other current liabilities	821.44	892.92	1,518.81	1,594.49
(c)	Provisions	470.28	334.97	910.42	1,108.42
(d)	Current tax liabilities (net)	-	-	7.55	220.81
	Total Current Liabilities	62,135.88	57,952.25	97,442.18	84,621.15
	Total Liabilities	84,305.86	76,641.32	132,309.62	114,900.75
	TOTAL EQUITY AND LIABILITIES	177,188.40	162,868.24	232,390.28	202,378.68



Place: Mumbai
Date: May 26, 2026

For Camlin Fine Sciences Limited



Ashish S. Dandekar
Chairman & Managing Director
DIN: 01077379



Registered Office:

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
CIN: L74100MH1993PLCO75361

+91 22 6700 1000

+91 22 2832 4404

corporate@camlinfs.com

www.camlinfs.com

CAMLIN FINE SCIENCES LIMITED
STANDALONE STATEMENT OF CASH FLOWS FOR THE YEAR ENDED MARCH 31, 2026

Particulars	INR (in Lakh)	
	For the year ended March 31, 2026	For the year ended March 31, 2025
Cash Flow from Operating Activities		
(Loss) Before Tax	(5,409.22)	(12,343.05)
Adjustment for:		
Depreciation and Amortisation Expense	5,367.71	5,252.66
Finance Costs	6,698.69	6,611.93
Foreign Exchange Loss / (Gain) (Unrealised)	(2,290.03)	677.81
(Gain)/Loss on sale of Property, Plant & Equipment and Intangible Assets	127.43	97.76
Allowance/(Reversal) of Credit Loss	(8.55)	(43.61)
Expense/(Reversal) recognised in respect of equity-settled share-based payments	125.31	27.99
Provision for Defined Benefit Plans	478.73	131.88
Interest Income	(615.31)	(587.70)
Interest Income on other financial assets	(3.66)	(7.06)
Lease income	(2.58)	-
Guarantee Commission	(27.27)	(27.27)
Provision for interest on MSME	487.93	467.96
Revaluation of inventory	-	(3,681.08)
Provision for doubtful advances	1,145.93	9,503.93
Net Gain arising on Financial Assets measured at Fair Value Through Profit or Loss (FVTPL)	(444.38)	(748.78)
Operating Profit before working capital changes	5,630.73	5,333.37
Adjustment for:		
Increase/(Decrease) in Non Financial Liabilities	(219.56)	(1,600.22)
Increase/(Decrease) in Financial Liabilities	289.56	(1,199.45)
(Increase)/Decrease in Non Financial Assets	2,360.22	(2,410.95)
(Increase)/Decrease in Financial Assets	(3,626.46)	1,811.48
Cash generated from operations	4,434.49	1,934.23
Taxes Paid (Net)	(38.51)	(120.43)
Net Cash Flow from Operating activities	4,395.98	1,813.80
Cash Flow from Investing Activities		
Purchase of Property, Plant & Equipment and Intangible Assets	(2,758.05)	(2,263.49)
Sale of Property, Plant & Equipment and Intangible Assets	36.94	94.11
Acquisition of subsidiary	(490.97)	-
Deposit in Escrow for acquisition of Minority Interest of Vinpai	(2,791.77)	-
Sale / (Purchase of current Investment)	0.00	(3,052.50)
Loan to Subsidiary and others	(229.74)	(165.98)
Maturity of / (Investment in) Fixed Deposit	3,034.50	(3,472.45)
Interest Received	159.52	93.97
Net Cash Flow used in Investing Activities	(3,039.57)	(8,766.34)
Cash Flow from Financing Activities		
Proceeds from Issue of Equity Shares under Right issue and Employee Stock Option Plan	53.78	22,312.64
Proceeds from / (Repayment of) Long Term Borrowings (Net)	3,565.24	(4,778.73)
Proceeds from / (Repayment of) Short Term Borrowings (Net)	(244.08)	(904.48)
Payment of lease liabilities	(764.60)	(773.48)
Interest Paid	(3,951.45)	(5,364.56)
Net Cash Flow from/(used in) Financing Activities	(1,341.11)	10,491.39
Net Increase in Cash & Cash Equivalents	15.30	3,538.85
Cash & Cash Equivalents at the beginning of the year	3,606.55	67.70
Cash & Cash Equivalents at the end of year	3,621.85	3,606.55

Note :

(a) The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard (Ind AS 7) - Statement of Cash Flows.

(b) Cash and Cash Equivalents comprises of :

Particulars	INR (in Lakh)	
	For the year ended March 31, 2026	For the year ended March 31, 2025
Balances with Banks in Current Accounts	3,618.58	22.18
Bank deposits with original maturity of less than three months	-	3,581.57
Cash on Hand	3.27	2.80
Cash and cash equivalents in Standalone Balance Sheet	3,621.85	3,606.55

Place: Mumbai
Date: May 26, 2026



For Camlin Fine Sciences Limited



Ashish S. Dandekar
Chairman & Managing Director
DIN: 01077379



Registered Office:

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
CIN: L74100MH1993PLC075361

+91 22 6700 1000

+91 22 2832 4404

corporate@camlinfs.com

www.camlinfs.com

CAMLIN FINE SCIENCES LIMITED

CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE YEAR ENDED MARCH 31, 2026

(Rs. in Lakh)

Particulars	For the year ended March 31, 2026 (Audited)	For the year ended March 31, 2025 (Audited)
Cash Flow from Operating Activities		
Profit / (Loss) Before Tax		6,457.67
Continuing operations	(3,198.61)	
Discontinued operations	5,524.20	(22,262.96)
Adjustment for:		
Depreciation and amortisation expense	7,396.23	7,366.90
Finance costs (Including of MSME Interest)	8,209.61	10,007.89
Foreign exchange loss / (gain) (unrealised)	(2,134.11)	2,576.58
Loss on sale/discard of Property, Plant & Equipment	127.43	295.37
Derecognition on liquidation of Subsidiary	(10,290.50)	14,619.23
Allowance for Doubtful debts and advances (Net)	1,374.96	206.79
Loss due to fire	763.43	-
Tariff refund receivable	(1,277.38)	-
Subsidiary acquisition cost	405.84	-
Net Expenses recognised in respect of equity settled share based payments	197.44	27.99
Provision for defined benefit plans and compensated absences	642.91	252.59
Interest income	(352.57)	(214.84)
Hyperinflationary effect on Consolidated Statement of Profit and Loss	136.38	(528.07)
Provision for write down of Inventory	-	(3,681.08)
Share of (profit)/loss of associate of step down subsidiary	(166.21)	(44.22)
Net gain arising on Financial Liabilities measured at Fair Value Through Profit or Loss (FVTPL)	(444.38)	(748.78)
Operating Profit before working capital changes	6,914.67	14,331.05
Adjustment for:		
Increase/(Decrease) in Non Financial Liabilities	(1,257.10)	26.37
Increase/(Decrease) in Financial Liabilities	7,232.04	(1,110.29)
(Increase)/Decrease in Non Financial Assets	(216.54)	(88.84)
(Increase)/Decrease in Financial Assets	(2,101.09)	(7,042.13)
Cash generated from operations	10,571.98	6,116.16
Taxes Paid (Net)	(2,365.12)	(3,816.58)
Net Cash Flow from Operating activities	8,206.86	2,299.59
Cash Flow from Investing Activities		
Purchase of Property, Plant & Equipment and Intangible Assets	(5,756.60)	(4,244.68)
Sale/ (Purchase) of non-current investments	(490.96)	-
Dividend received from associate company	-	81.69
Deposit in Escrow for acquisition of Minority Interest of Vinpai	(2,791.77)	-
Sale / (Purchase) of current Investment	-	(3,052.50)
Maturity of / (Investment in) Fixed Deposit (Net)	3,447.02	(405.13)
Interest Received	297.13	85.64
Net Cash Flows used in Investing Activities	(5,295.18)	(7,534.98)
Cash Flow from Financing Activities		
Proceeds from Issue of Equity Shares under Employee Stock Option Scheme / Plan	53.78	19.08
Proceeds from Issue of Equity Shares pursuant to Right Issue (Net of issue expenses)	-	22,293.55
Proceeds from / (Repayment of) Long Term Borrowings (Net)	6,894.79	(5,603.42)
Proceeds from / (Repayment of) Short Term Borrowings (Net)	(1,715.95)	(1,081.10)
Payment of lease liabilities	(1,639.99)	(1,050.41)
Interest Paid	(6,055.86)	(6,960.71)
Net Cash Flow from / (used in) Financing Activities	(2,463.23)	7,616.99
Net Increase/ (Decrease) in Cash & Cash Equivalents	448.45	2,381.59
Cash & Cash Equivalents at the beginning of the year	10,407.06	8,025.47
Cash & Cash Equivalents at the end of the year	10,855.51	10,407.06

Notes:

(a) The above Consolidated Statement of Cash Flows has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard (Ind AS 7) - Statement of Cash Flows.

(b) Cash and Cash Equivalents comprises of:

(Rs. in Lakh)

Particulars	As at	As at
	March 31, 2026	March 31, 2025
Balances with banks in current accounts	10,844.80	6,817.42
Bank deposits with original maturity of less than three months	-	3,581.57
Cash on hand	10.71	8.07
Cash and cash equivalents in Consolidated Balance Sheet	10,855.51	10,407.06



Place: Mumbai
Date: May 26, 2026

FOR CAMLIN FINE SCIENCES LIMITED

Ashish S. Dandekar
DIN: 01077379



Registered Office:

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
CIN: L74100MH1993PLC075361

+91 22 6700 1000

+91 22 2832 4404

corporate@camlinfs.com

www.camlinfs.com

Notes to Standalone and Consolidated Audited Financial Results:

- The above results which are published in accordance with Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended, have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 26, 2026. The financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, and other accounting principles generally accepted in India.
- The figures for the quarter ended March 31, of the respective financial years as reported in these results are the balancing figures between audited figures in respect of full financial year and the published year to date figures up to the end of the third quarter of the relevant financial year. Also, figures up to the end of the third quarter had only been reviewed and not subjected to audit.
- Other income / Other expense above relating to continuing operations includes net foreign exchange gain / (loss) for each reporting period as under:

Particulars	STANDALONE					CONSOLIDATED				
	QUARTER ENDED			YEAR ENDED		QUARTER ENDED			YEAR ENDED	
	31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025	31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025
	(Audited) (Refer Note 2)	(Unaudited)	(Audited) (Refer Note 2)	(Audited)	(Audited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited) (Refer Note 2)	(Audited)	(Audited)
Exchange gain	1,335.75	257.48	-	2,399.18	678.52	1,862.81	-	577.83	1,895.07	154.77
Exchange loss	-	-	54.55	-	-	-	868.95	-	-	-
Total Exchange gain / (loss)	1,335.75	257.48	(54.55)	2,399.18	678.52	1,862.81	(868.95)	577.83	1,895.07	154.77

The exchange gain / (loss) shown above excludes exchange gain / (loss) on derivative contracts accounted as cash flow hedge.

- Finance costs of continuing operation include foreign exchange gain / (loss) for each reporting period as under:

Particulars	STANDALONE					CONSOLIDATED				
	QUARTER ENDED			YEAR ENDED		QUARTER ENDED			YEAR ENDED	
	31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025	31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025
	(Audited) (Refer Note 2)	(Unaudited)	(Audited) (Refer Note 2)	(Audited)	(Audited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited) (Refer Note 2)	(Audited)	(Audited)
Exchange gain	-	-	21.82	-	-	-	57.04	573.21	-	-
Exchange loss	868.10	218.43	-	1,742.71	543.12	418.06	-	-	823.85	2,370.50
Total Exchange gain / (loss)	(868.10)	(218.43)	21.82	(1,742.71)	(543.12)	(418.06)	57.04	573.21	(823.85)	(2,370.50)

- During the quarter ended March 31, 2026, the Company has not issued or allotted employee stock options under any of the Employees Stock Option Plans (ESOP). 101,275 employee stock options have lapsed under ESOP-2018 while no employee stock options have lapsed under ESOP-2020 during the year ended March 31, 2026.
- On February 24, 2025, the Company and certain significant shareholders of Vinpai S.A. ("Vinpai"), including its founders, entered into a Share Purchase Agreement ("SPA") for acquisition by the Company of 2,723,316 ordinary shares of Vinpai at Euro 3.60/- per ordinary share. The consideration payable for the acquisition as per SPA was determined at Euro 9,803,937.60 equivalent to Rs. 10,170.60 lakh. On November 30, 2025, the said consideration was discharged by an issue of 4,106,181 fresh equity shares of the Company having a face value of Re. 1/- each and securities premium of Rs. 246.69/- per share. Further, the Company had invested Euro 3.30 million in Vinpai through subscription to 3,300 listed secured convertible bonds having a subscription price of Euro 1,000 per bond issued by Vinpai on February 24, 2025. These bonds matured on December 31, 2025, and were converted into 1,100,000 new ordinary shares of Euro 3/- per ordinary share of Vinpai at its fair value of Rs. 4,157.17 lakh. Pursuant to the issue of equity shares and conversion of bonds into equity shares of Vinpai by the Company, the Company now holds 3,823,316 equity shares of Vinpai representing 83.82% of Vinpai's outstanding share capital. The consolidated financial results of the Group include the audited results of Vinpai for the period from December 01, 2025, to March 31, 2026. Goodwill arising on this acquisition amounting to Rs. 16,810.5 Lakh has been recorded under the head 'Goodwill' on the balance sheet at March 31, 2026. Group is in the process of retrospectively identifying and fair-valuing certain intangible assets that may be bundled in the aforesaid goodwill within the permissible measurement period as per Para 45 of IND AS 103 - Business Combination. This acquisition has resulted into an open offer by the company to the minority shareholders of Vinpai as per the local regulations. Consequently, an open offer will be made for 711,363 equity shares at Euro 3.60 after approval of the concerned authorities. On March 30, 2026, Company has transferred Euro 2,560,907 equivalent to Rs. 2,791.77 lakh to an escrow account for the aforesaid offer.

7 Note on Exceptional Items

Exceptional items (expense), recognized in the Profit & Loss in the current quarter and year ended March 31, 2026 include :

I. In Standalone Financial Results -


- Provision/(reversal) for doubtful loan and interest receivable of Rs. (5.27 Lakh) & Rs. 1,145.93 Lakh;
- Impairment of Trade receivable of CFS Europe SpA, Italy upon its liquidation [Refer Note 8(a)]- Rs. 266.41 Lakh & Rs. 266.41 Lakh;
- Impact of the New Labour Codes on retirement benefits of Rs. Nil & Rs. 222.17 lakh, [Refer note 7(a)] ; and
- Reversal of impairment due to recovery of Nil & Rs. 7.56 Lakh.

II. In Consolidated Financial Results -

- Acquisition related cost of Vinpai, a subsidiary of Rs. 35.72 Lakh & Rs. 405.82 lakh;
- Provision/(reversal) for doubtful loan and interest receivable of Rs. (5.27 Lakh) & Rs. 1,145.93 Lakh;
- Impact of the New Labour Codes on retirement benefits of Nil & 222.17 Lakh, [Refer Note 7(a)];
- Impact of Loss due to fire [Refer Note 7(b)] of Rs. 763.43 Lakh & Rs. 763.43 Lakh; and
- Other Impairment loss (Net) Rs. Nil & Rs. 8.66 Lakh.

7(a) On November 21, 2025, the Government of India notified four Labour Codes (the Code on Wages 2019, the Code on Social Security 2020, the Industrial Relations Code 2020, and the Occupational Safety, Health and Working Conditions Code, 2020) consolidating existing labour laws (collectively "new Labour Codes"). In accordance with the new Labour Codes, the Company has currently estimated the incremental impact on retirement benefits consisting of gratuity and leave encashment to be Rs. 222.17 lakh. Considering the materiality and regulatory driven non-recurring nature of this development, it has been presented under "Exceptional Items" in the standalone / consolidated financials results. The Company continues to monitor the finalization of Central / State Rules and clarifications from the Government on other aspects of the Labour Codes and would provide appropriate accounting effect as and when such clarifications are issued / rules are notified.

7(b) Total impact of loss due to fire includes expected loss of Rs. 609.37 lakh which is net of insurance claim receivable related to a major fire incident occurred on February 21, 2026 at one of the two Blending units of CFS Do Brasil Industria, Comercio, Importacao e exportacao de Aditivos Alimenticios LTDA, a wholly owned subsidiary.





For Camlin Fine Sciences Limited

Ashish S. Dandekar
Chairman & Managing Director
DIN: 01077379

8 Discontinued Operations:

8(a) Pursuant to the liquidation order dated March 17, 2026 issued by the local statutory authority in Italy, an official liquidator has been appointed to liquidate CFS Europe SpA, a wholly owned subsidiary. Consequent to this process and the consequential loss of control, the net liabilities of the subsidiary have been derecognized effective the date of the liquidation order. Further all the operations of the subsidiary have been classified as discontinued operations in line with the requirements of IND AS 105 (Non-current Assets Held for Sale and Discontinued Operations) in the Statement of Result for the quarter / year and for all prior periods presented. The resulting gain on derecognition of net liabilities of Rs 10,290.51 Lakh has been recognized and included in Profit/(Loss) from "Discontinued Operations". Operational loss of the Discontinued Operations for the period from April 1, 2025 till the date of liquidation order amounting to Rs. 4,228.71 Lakh have been adjusted in Profit/(Loss) from Discontinued Operations.

8(b) The entire operations of the subsidiary CFS Wanglong Flavours (Ningbo) Co. Ltd. ('CFS Wanglong'), China were considered unviable and stopped with effect from February 19, 2021. Accordingly, the results of CFS Wanglong amounting to Rs 537.6 Lakhs for the year ended March 31, 2026 continue to be classified and disclosed under the head Profit/(Loss) from Discontinued Operations.

9 In the current quarter and the year, the refund receivable with respect to tariffs paid under the International Emergency Economic Powers Act of USA amounting to Rs. 1,035.09 Lakh has been included in the operational revenue of the Standalone Financial results while Rs. 1,277.38 Lakh has been adjusted in "Cost of Materials Consumed" in Consolidated Financial results.

10 The Company's operations constitute a single business segment i.e. Speciality Chemicals.

Place: Mumbai
Date: May 26, 2026



Registered Office:

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
CIN: L74100MH1993PLC075361

+91 22 6700 1000



+91 22 2832 4404



corporate@camlinfs.com



www.camlinfs.com

KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

INDEPENDENT AUDITOR'S REPORT

TO THE BOARD OF DIRECTORS OF CAMLIN FINE SCIENCES LIMITED

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying annual Standalone Financial Results of **Camlin Fine Sciences Limited** ("the Company") for the year ended March 31, 2026, together with the Notes thereon, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("LODR Regulations"), duly initialled by us for identification.

In our opinion and to the best of our information and according to the explanations given to us these Standalone Financial Results:

- i. are presented in accordance with the requirements of Regulation 33 of the LODR Regulations in this regard; and
- ii. give a true and fair view in conformity with the applicable accounting standards ("Ind AS") and other accounting principles generally accepted in India of the net loss and other comprehensive income and other financial information of the Company for the year ended March 31, 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Standalone Financial Results* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Board of Directors' Responsibilities for the Standalone Financial Results

These Standalone Financial Results have been prepared on the basis of the annual standalone financial statements. The Company's Board of Directors are responsible for the preparation and presentation of these Standalone Financial Results that give a true and fair view of the net loss and other comprehensive income and other financial information in accordance with the Indian Accounting Standard prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. The Board of Directors of the Company are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and are free from material misstatement, whether due to fraud or error.



LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001
TEL.: (91) (22) 6158 6200, 6158 7200 FAX: (91) (22) 6158 6275

In preparing the Standalone Financial Results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Standalone Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Standalone Financial Results, including the disclosures, and whether the Standalone Financial Results represent the underlying transactions and events in a manner that achieve fair presentation.

We communicate with those charged with governance of the Company regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



**KALYANIWALLA
& MISTRY LLP**

Other Matter


The Standalone Financial Results include the results for the quarter ended March 31, of the respective financial years, being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the end of the third quarter of the relevant financial year which were subjected to limited review by us.

Our opinion on the Standalone Financial Results is not modified in respect of the above matter.

For **Kalyaniwalla & Mistry LLP**

Chartered Accountants

Firm Registration No.: 104607W/W100166



Anil A. Kulkarni

Partner

Membership No.: 047576

UDIN: 26047576TGCIQQ4046

Place: Mumbai

Date: May 26, 2026



KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

INDEPENDENT AUDITOR'S REPORT

TO THE BOARD OF DIRECTORS OF
CAMLIN FINE SCIENCES LIMITED

Report on the Audit of the Consolidated Financial Results


Opinion

We have audited the accompanying annual Consolidated Financial Results of **Camlin Fine Sciences Limited** (hereinafter referred to as the "Holding Company") and its subsidiaries (Holding Company and its subsidiaries together referred to as the "Group") and an associate of a step down subsidiary (refer paragraph below) for year ended March 31, 2026, together with the notes thereon ("the Statement") attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India ("the SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("LODR Regulations"), duly initialled by us for identification.

In our opinion and to the best of our information and explanations given to us and based on the consideration of the reports of the other auditors on separate audited financial results of the subsidiaries and an associate of a step down subsidiary, the aforesaid Consolidated Financial Results:

(i) include the financial results of the Holding Company and following entities:

Sr. No.	Name of the Entity	Relationship
Incorporated In India		
i.	Chemolutions Chemicals Ltd.	Subsidiary
ii.	AlgalR Nutra Pharms Private Limited	Subsidiary
Incorporated Outside India		
iii.	CFS North America LLC	Wholly owned subsidiary
iv.	CFS Do Brasil Indústria, Comércio, Importação e Exportação De Aditivos Alimentícios LTDA	Wholly owned subsidiary
v.	Solentus North America Inc	Wholly owned subsidiary
vi.	CFS Europe S.P.A (Under liquidation from March 17, 2026)	Wholly owned subsidiary
vii.	Dresen Quimica S.A.P.I de C.V.	Wholly owned subsidiary
viii.	Industrias Petrotec De Mexico S.A. de C.V.	Step down subsidiary
ix.	Nuvel, S.A.C.	Step down subsidiary
x.	Britec, S.A.	Step down subsidiary
xi.	Inovel, S.A.S	Step down subsidiary
xii.	Grinel, S.R.L	Step down subsidiary
xiii.	CFS Wanglong Flavors (Ningbo) Co. Ltd.	Subsidiary
xiv.	CFS Pahang Asia Pte. Ltd (Struck off w.e.f. November 04, 2025).	Subsidiary



LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001
TEL.: (91) (22) 6158 6200, 6158 7200 FAX: (91) (22) 6158 6275

**KALYANIWALLA
& MISTRY LLP**

Sr. No.	Name of the Entity	Relationship
xv.	CFS Argentina S.A.	Step down subsidiary
xvi.	CFS Chile De SPA	Step down subsidiary
xvii.	CFS PP (M) SDN. BHD	Subsidiary
xviii.	Vitafor Invest NV, Belgium	Step down subsidiary
xix.	Vitafor NV	Step down subsidiary
xx.	Addi-Tech NV	Step down subsidiary
xxi.	Vitafor China Ltd.	Step down subsidiary
xxii.	Vial SARL (w.e.f. June 11, 2024)	Associate Company of a Step-down subsidiary
xxiii.	Vinpai S. A. (w.e.f. November 30, 2025)	Subsidiary
xxiv.	Based Algae & Plants, France (w.e.f. November 30, 2025)	Step-down subsidiary

- (ii) are presented in accordance with the requirements of Regulation 33 of the LODR Regulations, in this regard; and
- (iii) give a true and fair view in conformity with the applicable Accounting Standards (“Ind AS”) and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Group and an associate of a step down subsidiary for the year ended March 31, 2026.

Basis for Opinion

We conducted our audit in accordance with Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (“the Act”). Our responsibilities under those standards are further described in the *Auditor’s Responsibilities for the Audit of the Consolidated Financial Results* section of our report. We are independent of the Group and an associate of a step down subsidiary in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the consolidated financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI’s Code of Ethics. We believe that the audit evidence obtained by us and other auditor in terms of their reports referred to in “Other Matters” paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Board of Directors’ Responsibilities for the Consolidated Financial Results

These Consolidated Financial Results have been prepared on the basis of the Consolidated Annual Financial Statements. The Holding Company’s Board of Directors are responsible for the preparation and presentation of these Consolidated Financial Results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Group including an associate of a step down subsidiary in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. The respective Board of Directors of the companies included in the Group and an associate of a step down subsidiary are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and an associate of a step down subsidiary and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of these Consolidated Financial Results by the Board of Directors of the Holding Company, as aforesaid.



In preparing the Consolidated Financial Results, the respective Board of Directors of the companies included in the Group and an associate of a step down subsidiary are responsible for assessing the ability of the Group and an associate of a step down subsidiary to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group and an associate of a step down subsidiary or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and an associate of a step down subsidiary are responsible for overseeing the financial reporting process of the Group and an associate of a step down subsidiary.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Consolidated Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and an associate of a step down subsidiary to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and an associate of a step down subsidiary to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Consolidated Financial Results, including the disclosures, and whether the Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.



**KALYANIWALLA
& MISTRY LLP**

- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group and an associate of a step down subsidiary to express an opinion on the Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Consolidated Financial Results of which we are the independent auditors. For the other entities included in the Consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in Consolidated Financial Results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.


We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the LODR Regulations, as amended, to the extent applicable.

Other Matters

- a) The Consolidated Financial Results include the audited financial results of 14 subsidiaries incorporated out of India and 2 subsidiaries in India, whose Financial Results reflect Group's share of total assets (before consolidation adjustments) of Rs.1,18,272.53 lakh as at March 31, 2026, Group's share of total revenue (before consolidation adjustments) of Rs. 32,618.86 lakh and Rs. 1,16,871.51 lakh and Group's share of total net profit/(loss) after tax (before consolidation adjustments) of Rs. (350.27) lakh and Rs. 162.71 lakh, total comprehensive income (before consolidation adjustments) of Rs. 231.68 lakh and Rs. 4078.98 lakh for the quarter and year ended March 31, 2026, respectively, as considered in the Consolidated Financial Results, which have been audited by their respective independent auditors. The independent auditors' report on financial results of these entities have been furnished to us and our opinion on the Consolidated Financial Results, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the report of such auditors and the procedures performed by us are as stated in paragraph above.

The subsidiaries which are incorporated outside India, whose financial results and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been audited by other auditors under generally accepted auditing standards applicable in their respective countries. The Company's management has converted the financial results of such subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India (Indian Accounting Standards 'Ind AS'). We have audited these conversion adjustments made by the Company's management. Our opinion in so far as it relates to the amounts and disclosures included in respect of such subsidiaries incorporated outside India is based on the report of the other auditors and the conversion adjustments made by the Holding Company's Management and audited by us.

- b) i) The Consolidated Financial Results include the unaudited financial results of 6 subsidiaries, whose Financial Results reflect Group's share of total assets (before consolidation adjustments) of Rs.3,446.14 lakh as at March 31, 2026, Group's share of total revenue (before consolidation adjustments) of Rs.113.10 lakh and Rs.1,238.08 lakh, Group's share of total net profit/(loss) after tax (before consolidation adjustments) of Rs. 29.19 lakh and Rs. (1,189.87) lakh, total comprehensive income (before consolidation adjustments) loss of Rs. 218.37 lakh and Rs.952.99 lakh for the quarter and year ended March 31, 2026, respectively, as considered in the Consolidated Financial Results.



**KALYANIWALLA
& MISTRY LLP**

ii) The Consolidated Financial Results include the unaudited financial results of a subsidiary which is under liquidation from March 17, 2026 (referred in para (i) above), whose Financial Results reflect Group's share of total assets (before consolidation adjustments) of Rs.7,310.79 lakh as at March 17, 2026, Group's share of total revenue (before consolidation adjustments) of Rs.1,478.51 lakh and Rs. 7,089.54 lakh, Group's share of total net loss after tax (before consolidation adjustments) of Rs. 1,212.93 lakh and Rs. 7,838.06 lakh, total comprehensive income (before consolidation adjustments) loss of Rs. 1,291.95 lakh and Rs.9,110.80 lakh for the period from January 1, 2026 to March 17, 2026 and for the period from April 1, 2025 to March 17, 2026, respectively, as considered in the Consolidated Financial Results. The unaudited financial statements of this subsidiary were reviewed by its independent auditor up to December 31, 2025. The results of this subsidiary for the period from January 01, 2026 to March 17, 2026 (date of liquidation) are unaudited and are not considered material according to the information and explanations given to us by the Board of Directors.

iii) The Statement also includes the Group's share of net profit (before consolidation adjustments) and total comprehensive income (before consolidation adjustments) of Rs.138.29 Lakh and Rs.166.21 Lakh for the quarter and year ended March 31, 2026 respectively as considered in the consolidated audited financial results, in respect of an associate of a step down subsidiary, located outside India, which have not been audited.

These unaudited financial Statements have been furnished to us by the Board of Directors and our opinion on these Consolidated Financial Results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and an associate of a step down subsidiary is based solely on such unaudited Financial Statements. In our opinion and according to the information and explanations given to us by the Board of Directors, these Financial Statements are not material to the Group.

Our opinion on these Consolidated Financial Results is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the Financial Results certified by the Board of Directors.

c) The Consolidated Financial Results include the results for the quarter ended March 31, of the respective financial years, being the balancing figures between audited figures in respect of full financial year and the published unaudited year to date figures up to the end of the third quarter of the relevant financial year which were subject to limited review by us.

Our opinion on these Consolidated Financial Results is not modified in respect of the above matters.

For Kalyaniwalla & Mistry LLP

Chartered Accountants

Firm Registration No.: 104607W/W100166



Anil A. Kulkarni


Partner

Membership No.: 047576

UDIN: 26047576EVKFDZ1620

Place: Mumbai

Date: May 26, 2026





For Camlin Fine Sciences Limited

Ashish S. Dandekar

Ashish S. Dandekar
Chairman & Managing Director
DIN: 01077379

STATEMENT OF AUDITED FINANCIAL RESULTS FOR QUARTER AND YEAR ENDED MARCH 31, 2026											
No.	PARTICULARS	STANDALONE					CONSOLIDATED				
		QUARTER ENDED			YEAR ENDED		QUARTER ENDED			YEAR ENDED	
		31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025	31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1	Total Income from Operations	18,351.65	21,892.16	27,259.63	83,791.82	88,649.13	42,481.12	44,051.07	43,158.42	172,330.81	162,868.75
2	Net Profit / (Loss) for the period from continuing operations (before tax and exceptional items)	(1,402.48)	(361.12)	1,163.23	(3,782.27)	(2,742.84)	268.61	(1,006.34)	4,295.48	(652.60)	7,439.19
3	Net Profit / (Loss) for the period before tax from continuing operations (after exceptional items)	(1,663.62)	(1,726.93)	1,189.68	(5,409.22)	(12,343.05)	(526.27)	(2,757.47)	3,736.08	(3,198.61)	6,457.67
4	Total Net Profit / (Loss) for the period after tax (after exceptional items)	(564.95)	(1,299.66)	1,561.84	(3,296.62)	(7,631.05)	8,627.73	(3,710.29)	11.00	2,354.32	(15,811.94)
5	Net Profit / Loss for the period after tax and non-controlling interests (after exceptional items)						8,820.19	(3,622.99)	(72.40)	2,762.72	(13,904.59)
6	Total Comprehensive Income for the period	(664.17)	(1,267.19)	1,756.15	(3,766.20)	(7,685.08)	7,438.53	(3,272.41)	590.47	2,698.04	(17,035.43)
7	Equity Share Capital	1,920.92	1,920.92	1,879.21	1,920.92	1,879.21	1,920.92	1,920.92	1,879.21	1,920.92	1,879.21
8	Other Equity				90,961.62	84,347.71				102,167.09	88,288.09
9	Earnings per share (of Re 1/-each) (not annualised)										
	-Basic Rs.	(0.29)	(0.69)	0.86	(1.74)	(4.41)	4.59	(1.91)	(0.04)	1.46	(8.03)
	-Diluted Rs.	(0.29)	(0.69)	0.85	(1.74)	(4.41)	4.54	(1.91)	(0.04)	1.44	(8.03)

Note -The above information is an extract of the detailed format of audited results for the quarter ended March 31, 2026 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the audited results for the quarter March 31, 2026 are available on the Company's website at www.camlinfs.com and the Stock Exchange websites i.e. www.bseindia.com and www.nseindia.com.

Place: Mumbai
Date: May 26, 2026

Registered Office:

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
CIN: L74100MH1993PLC075361

+91 22 6700 1000



+91 22 2832 4404



corporate@camlinfs.com



www.camlinfs.com

Disclosure under Regulation 30 of read with Schedule III of the SEBI Listing Regulations and SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026

Particulars	Details			
	Name	M/s. ABK & Associates (Cost Auditor)	M/s. Mahajan & Aibara (Internal Auditor)	Mr. Pankaj Pandey (Chief Financial Officer)
Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment	Appointment	Appointment	Change in designation
Date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment	Date of appointment: May 26, 2026 Term of Appointment: FY 2026-27	Date of appointment: May 26, 2026 Term of Appointment: FY 2026-27	Date of appointment: August 18, 2026	Date of Change in designation: August 18, 2026
Brief profile (in case of appointment)	M/s. ABK & Associates is a partnership firm was promoted in the year 1989 by Cost Accountants with meticulous track record and sound professional background. The firm is established to provide broad range of integrated services comprising of auditing, advisory, liaison, compliance and facilitation in the field of Management Consultancy, Cost Consultancy, Project Finance, Audit, GST & Export- Import to public sector, private sector and government sector.	M/s. Mahajan & Aibara offers Internal Audit & Risk Consulting related services. Since 1979, risk related services have been their sole priority and specialty. Their expertise and brand of audit are widely recognized. They serve India's largest Corporate Houses, Blue-chip, Fortune 500, MNCs, and both public and private companies in India and across the globe. Their clients span all industries. They offer the best of large audit firms combined with the personalized attention of a boutique agency. Every	Mr. Pankaj Pandey is a qualified Chartered Accountant and certified CISA with 22 years of experience and expertise spread across of gamut of Finance & Accounts leadership role covering Financial Planning & Control, Long Term Strategic Planning, Budgeting & MIS, Consolidated Financial Reporting, Treasury & Taxation, Business Finance & Partnering, Internal Audit, Enterprise Risk Management, Taxation, Internal & External Stakeholder Management.	Mr. Santosh Parab is a qualified Chartered Accountant with over two decades of experience in the auditing profession. He previously worked with B.K. Khare & Co, an Indian accounting firm. He has been associated with the Company for nine years, contributing his invaluable knowledge, expertise, and experience to the organization's continued success.


Registered Office:

 Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
 CIN: L74100MH1993PLCO75361


+91 22 6700 1000



+91 22 2832 4404



corporate@camlinfs.com



www.camlinfs.com

		client is directly served by partner-level professionals.	He previously worked with Transasia Bio-Medicals Ltd, Sun Pharmaceutical Industries Ltd, KPMG, Glenmark Pharmaceuticals Ltd, Larsen & Toubro Ltd.	
disclosure of relationships between directors (in case of appointment of a director)	Not Applicable	Not Applicable	Not Applicable	Not Applicable
Information as required pursuant to BSE Circular ref. no. LIST/COMP/14/2018-19 and NSE ref. no. NSFJMU2018/24, dated June 20 2018.	Not Applicable	Not Applicable	Not Applicable	Not Applicable



Registered Office:

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
CIN: L74100MH1993PLCO75361



+91 22 6700 1000



+91 22 2832 4404



corporate@camlinfs.com



www.camlinfs.com